AIMS OF THE STUDY: 1. To perform a retrospective, epidemiological analysis of cases of reactive lymphadenopathy and atypical reactive lymphoid hyperplasia (ARLH) received in the Department of Anatomical Pathology, UCT and GSH, over a 5 year period, in order to determine the number of cases of ARLH, and the frequency of the various subtypes of reactive lymphoid. hyperplasia, so as to provide base-line information for further studies. 2. To set up IN SITU HYBRIDIZATION (ISH) for detection of Epstein-Barr virus (EBV)-encoded RNA's (EBERs) in latently infected cells in selected cases, to determine if virus is present in ARLH. 3. To perform immunohistochemical analysis for the detection of EBY-derived latent membrane protein (LMP) in those cases subjected to ISH.

Thesis (Ph. D.)--Ohio State University, 2006. / Title from first page of PDF file. Includes bibliographical references (p. 87-93).

Thesis (M.S.)--West Virginia University, 2000. / Title from document title page. Document formatted into pages; contains ix, 154 p. : ill. Includes abstract. Includes bibliographical references (p. 137-143).

No description available.

No description available.

Introduction: Cystic lymphoid hyperplasia (CLH) is a common yet under recognised entity affecting the parotid gland in HIV infected patients. This is the largest global clinicopathological study of CLH to date consisting of 167 cases (85M, 82F). Aim: To define the clinical parameters, histology and immunopathological features of CLH with a view to elucidating the aetio-pathogenesis. Material and Methods: This retrospective study on archival cases of CLH included patient’s age, race, gender, nature of CLH, HIV status, CD4 counts and viral loads where available. Of the 167 confirmed cases of CLH, 109 cases were histologically reviewed and 25 cases were immunohistochemically analysed with CD3, CD20, CD4, CD8 and p24 using standard procedures. Ethics clearance (M080927 and M080850) was obtained. Results: CLH mainly affects the parotid gland with a male predominance. Submandibular gland (p = 0.27) and bilateral parotid involvement favours females (2:1). CLH affects females at a younger mean age in both the parotid and submandibular glands (36.5, 31 years) respectively compared to males (40.9, 42.4 years) (p = 0.0032). Intra-lymph nodal origin is favoured with 76.1% of cases occurring within entrapped salivary gland remnants. P24 staining reveals ~90% specificity in HIV associated CLH. Immunostaining showed a CD8:CD4 of ~1:1 except in selected cases where CD4 was decreased in the interfollicular areas. Conclusion: CLH is the preferred term to describe bilateral parotid enlargement in HIV infected patients. This study strongly supports origin of CLH following ductal ectasia of entrapped salivary gland inclusions within atypical lymphoid hyperplasia arising within lymph nodes in the context of an HIV setting. CLH should be classified as an orofacial lesion strongly associated with HIV and AIDS.

No description available.

Thesis (M.D.S.)--University of Hong Kong, 1994. / Cover title. Includes bibliographical references (p. 304-334).

Thesis (M.D.S.)--University of Hong Kong, 1994. / Cover title. Includes bibliographical references (p. 304-334). Also available in print.

Orientador: Wilter Ricardo Russiano Vicente / Banca: Aracélle Elisane Alves / Banca: Fabiana Ferreira de Souza / Banca: Maria Denise Lopes / Banca: Maricy Apparicio Ferreira / Resumo: A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, no entanto, sua fisiopatologia não está totalmente compreendida. O objetivo principal do tratamento da HPB é controlar o crescimento do órgão, prevenir complicações e efeitos colaterais. Desta maneira, o efeito da toxina botulínica tem sido investigado, mostrando bons resultados no homem. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da finasterida e da TB-A no tratamento da HPB canina. Para tanto, 24 cães adultos foram divididos aleatoriamente em quatro grupos e submetidos à administração de solução fisiológica 0,9%, 5 mg de finasterida, 500 U de TB-A ou 500 U de TB-A associada a finasterida, e avaliados durante 16 semanas. Complicações locais ou alterações sistêmicas não foram observadas nos animais pertencentes aos grupos experimentais. Após 16 semanas da administração de 5 mg de finasterida o volume prostático reduziu 45,3% e ocorreu um aumento de 5 vezes nas taxa de morte celular. Comparando-se os valores do volume prostático após 16 semanas da aplicação de 500 U de TB-A ou 500 U de TB-A associada a finasterida com os valores basais, observamos uma redução de 30,9 e 51,3%, respectivamente. Neste mesmo período, ocorreu um aumento de seis e oito vezes da taxa de apoptose nos animais do grupo III e IV. Os resultados sugerem que os três protocolos terapêuticos promovem significativa redução do volume prostático e esta se deve a apoptose celular ao invés de necrose. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina / Abstract: Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 - 2 years, however, its pathophysiology is not fully elucidated. The main goal of BPH is to control the growth of the prostate, to prevent complications, and to minimize the adverse effects. Thus, the effect of botulinum toxin A (BT-A) has been investigated in humans with good results. Based on that, this study aimed to provide information about the effects of finasteride and BT-A in the treatment of BPH in dogs. For that, 24 adults dogs were randomly divided in four groups and submitted to administration of saline solution, 5 mg of finasteride, 500 of BT-A or 500 U of BT-A associated with finasteride, and evaluated along 16 weeks. Local complications and systemic effects were not observed. After 16 weeks of the application of 5 mg of finasteride the prostatic volume decreased 45,3% and occurred a 5-fold increased in the rate of cell death. Comparing the values of the prostatic volume after 16 weeks of administration of 500 U of BT-A or 500 U BT-A associated with finasteride with the baseline, a decrease of 30,9 and 51,3% were observed, respectively. In the same period, a increase of 6 and 8 times occurred in the rate of apoptosis in the animals of group III and IV. The results suggest that all 3 treatments protocols further significant reduction in the prostate volume have shown to significantly reduce the volume of prostate, and this reduction is due apoptosis instead necrosis. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate / Doutor